MNPR Monopar Therapeutics

  1. Stocks
  2. Healthcare
  3. NASDAQ: MNPR

Price (delayed)

$89.38

Market cap

$599.93M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.2

Enterprise value

$547.28M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 11

Monopar Therapeutics is a clinical-stage biotechnology company with late-stage ALXN-1840 for Wilson disease, and radiopharma programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late ...

Highlights
The equity has soared by 151% YoY but it has contracted by 3.4% from the previous quarter
The EPS has grown by 43% YoY but it has contracted by 14% from the previous quarter
Monopar Therapeutics's quick ratio has decreased by 40% from the previous quarter
The net income has declined by 19% since the previous quarter and by 3.1% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.monopartx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of MNPR

MNPR stock price

How has the Monopar Therapeutics stock price performed over time
Intraday
-7.5%
1 week
-11.9%
1 month
-17.03%
1 year
32.08%
YTD
36.88%
QTD
-3.47%

Financial performance

How have Monopar Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$22.12M
Net income
-$17.84M
Gross margin
N/A
Net margin
N/A
The net income has declined by 19% since the previous quarter and by 3.1% year-on-year
The operating income has contracted by 18% from the previous quarter and by 16% YoY

Price vs fundamentals

How does MNPR's price correlate with its fundamentals

Growth

What is Monopar Therapeutics's growth rate over time

Valuation

What is Monopar Therapeutics stock price valuation
P/E
N/A
P/B
4.58
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 43% YoY but it has contracted by 14% from the previous quarter
The equity has soared by 151% YoY but it has contracted by 3.4% from the previous quarter
MNPR's price to book (P/B) is 90% more than its 5-year quarterly average of 2.6 and 41% more than its last 4 quarters average of 3.5

Efficiency

How efficient is Monopar Therapeutics business performance
Monopar Therapeutics's ROIC has soared by 86% YoY and by 12% from the previous quarter
MNPR's return on equity has surged by 69% year-on-year but it is down by 2.3% since the previous quarter
The return on assets has surged by 68% year-on-year

Dividends

What is MNPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MNPR.

Financial health

How did Monopar Therapeutics financials performed over time
The total assets has surged by 151% year-on-year but it has declined by 2.2% since the previous quarter
The total liabilities has soared by 148% year-on-year and by 59% since the previous quarter
The company's debt is 100% lower than its equity
The equity has soared by 151% YoY but it has contracted by 3.4% from the previous quarter
The company's debt rose by 34% YoY but it fell by 18% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.